Therefore, it is reasonable to deduce that patients with dyslipidemia may get more benefits from PCSK9 inhibitors, such as monoclonal antibody [21], if it be used before the application of lipid-lowering drugs in clinical practice. The gene discussed is PCSK9; the disease is metabolic syndrome.